Skip to main content

Table 1 Main characteristics at diagnosis and therapy at frontline, all patients (n = 400)

From: Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma

 

Overall

(n = 400)

No change in therapy based on MRD

(n = 333)

Change in therapy based on MRD

(n = 67)

Male (%)

55

57

45

Mean age, years (sd)

58.9 (0.4)

59.2 (0.7)

57.1 (1.3)

Myeloma type, (%)

 IgG

55

56

46

 IgA

19

19

20

 Light chain only

19

17

27

High risk cytogenetics*, (%)

17

17

16

ISS, (%)

 I

38

35

40

 II

26

28

38

 III

35

33

27

Hemoglobin, (g/dL) (sd)

12.5 (0.7)

12.6 (0.7)

12.1 (1.2)

High LDH levels, (%)

20

20

21

Induction treatment, (%)

 CyBorD

19

19

19

 VRD/VTD

45

49

40

 Others

36

32

41

 ASCT, yes (%)

78

78

81

 Maintenance, yes (%)

82

82

91

  1. CyBorD: bortezomib, cyclophosphamide, dexamethasone; VRD: bortezomib, lenalidomide, dexamethasone; VTD: bortezomib, thalidomide, dexamethasone; ASCT: Autologous Stem Cell Transplantation. When we compared both groups, we did not find any statistical significance, p > 0.05 in all comparisons
  2. *High-risk cytogenetics was defined as del 17p; t(4;14), t(14;16) or t(14;20). When we compared both groups, we did not find any statistical significance, p > 0.05 in all comparisons